These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6886975)

  • 1. Estimation of absolute bioavailability assuming steady state apparent volume of distribution remains constant.
    Collier PS; Riegelman S
    J Pharmacokinet Biopharm; 1983 Apr; 11(2):205-14. PubMed ID: 6886975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some considerations on the estimation of steady state apparent volume of distribution and the relationships between volume terms.
    Collier PS
    J Pharmacokinet Biopharm; 1983 Feb; 11(1):93-105. PubMed ID: 6875813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.
    Rubin GM; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):437-50. PubMed ID: 6527233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption.
    Deng J; Jhandey A; Zhu X; Yang Z; Yik KFP; Zuo Z; Lam TN
    PLoS One; 2018; 13(8):e0203361. PubMed ID: 30169515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further considerations on model-independent bioavailability estimation.
    Hwang S; Kwan KC
    J Pharm Sci; 1980 Jan; 69(1):77-80. PubMed ID: 7354448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. I. Log-convex drug disposition curves.
    Weiss M
    J Pharmacokinet Biopharm; 1986 Dec; 14(6):635-57. PubMed ID: 3820094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.
    Hinderling PH
    Biopharm Drug Dispos; 2003 Jan; 24(1):1-16. PubMed ID: 12516074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of ratios of different volumes of distribution in pharmacokinetics.
    Wagner JG
    Biopharm Drug Dispos; 1983; 4(3):263-70. PubMed ID: 6626701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Method of residuals: estimation of absorption and elimination rate constants having comparable values.
    Macheras P
    Biopharm Drug Dispos; 1987; 8(1):47-56. PubMed ID: 3580512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic transfer functions and generalized clearances.
    Siegel RA
    J Pharmacokinet Biopharm; 1986 Oct; 14(5):511-21. PubMed ID: 3806373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of pharmacokinetic parameters: influence of the sampling site.
    Weiss M
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):167-75. PubMed ID: 6491899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss.
    Berezhkovskiy LM
    J Pharm Sci; 2007 Jun; 96(6):1638-52. PubMed ID: 17117429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can non-renal clearance and/or bioavailability of drugs be assessed reliably in renal impairment studies with oral drug administration?
    Yu Y; Hinderling PH
    Int J Clin Pharmacol Ther; 2024 Mar; 62(3):129-141. PubMed ID: 38174884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial slope technique for estimation of the apparent volume of distribution during constant-rate intravenous infusion.
    Cocchetto JF; Cocchetto DM; Bjornsson TD; Bergan T
    J Pharm Sci; 1984 Jan; 73(1):58-62. PubMed ID: 6694084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of drugs with long elimination half-lives.
    Urso R; Aarons L
    Eur J Clin Pharmacol; 1983; 25(5):689-93. PubMed ID: 6141052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.